Table 2.
TEAEs and all grade 3 or 4 TRAEs observed in at least 5% of patients.
| 2 mg (N = 27) | 8 mg (N = 23) | |||
|---|---|---|---|---|
| Event | Any grade TEAE | Grade 3–4 TRAE | Any grade TEAE | Grade 3–4 TRAE |
| Any | 92.6 | 14.8 | 100 | 34.8 |
| ALT Increased | 7.4 | — | 8.7 | — |
| Anemia | 14.8 | — | 21.7 | — |
| Anxiety | — | 13 | — | |
| Chills | 11.1 | — | 43.5 | — |
| Constipation | 14.8 | — | 17.4 | — |
| Cough | 11.1 | — | 8.7 | — |
| Decreased appetite | 11.1 | — | 13 | — |
| Dehydration | — | 13 | 4.3 | |
| Diarrhea | — | 30.4 | — | |
| Dizziness | 18.5 | — | 4.3 | — |
| Dysphagia | 18.5 | — | 26.1 | — |
| Fatigue | 55.6 | — | 73.9 | 17.4 |
| Headache | 11.1 | — | 43.5 | 4.3 |
| Hyponatremia | 11.1 | 4.3 | 8.7 | — |
| Injection site erythema | 3.7 | — | 17.4 | — |
| Injection site pain | — | 26.1 | 8.7 | |
| Injection site swelling | 7.4 | — | 13 | — |
| Insomnia | 11.1 | — | 8.7 | — |
| Malaise | — | 52.2 | — | |
| Myalgia | 3.7 | — | 39.1 | 8.7 |
| Nausea | 29.6 | — | 34.8 | — |
| Pneumonia | 14.8 | — | 4.3 | — |
| Pruritus | 7.4 | — | 17.4 | — |
| Pyrexia | 22.2 | — | 26.1 | — |
| Tumor hemorrhage | 18.5 | — | — | — |
| Tumor pain | 14.8 | — | 8.7 | — |
| Vomiting | 18.5 | — | 13 | — |
Note: No grade 5 treatment-related adverse events were observed.